Pharvaris (PHVS) Stock Forecast & Price Target

PHVS price $33.13 +0.31 +0.94%

Ticker
PHVS
Price
$33.13
Change
+0.31 +0.94%
Market cap ?
$2.31B
P/E ?
-10.38
Forward P/E ?
19.52
Dividend yield ?
0.00%
Beta ?
-2.46
Sector
Healthcare
Industry
Biotechnology

Financials

20182019202020212022202320242025
00000000

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema…

Forecast

Consensus Buy from 14 analysts. Average price target $60.73, +83.3% versus the current price. Low $44.00. High $75.00.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Analysts have an average 12-month price target of $60.73 for Pharvaris (PHVS), 83.3% above the current price of $33.13. Of 14 analysts covering the stock, 14 rate it Buy or Strong Buy, 0 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.

Forecasts are third-party estimates and often wrong. They are not investment advice.

PHVS price target

12-month price target
Low$44.00
Average$60.73
High$75.00

The average is 83.3% above the current price of $33.13.

Is Pharvaris a buy or sell?

Of 14 analysts, 14 rate Pharvaris Buy or Strong Buy, 0 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.

Pharvaris earnings and revenue forecast

Analyst averages on file: 2026, EPS -2.81, revenue $1.14 million. 2027, EPS -2.72, revenue $33.02 million.

PHVS score and fair value

The Stocklytics Score, when it is published for PHVS, averages value, quality, and growth on a 0–100 scale. It is not a price target. Fair value is a separate estimate on the fair value tab.

PHVS forecast FAQs

What is the PHVS price target?

$60.73 average, with a published range of $44.00 to $75.00.

Is Pharvaris a buy or sell?

The consensus is Buy from 14 analysts. This is not a recommendation.

What is the Pharvaris stock forecast for 2026?

Analysts' average EPS estimate for 2026 on file is -2.81. The average revenue estimate is $1.14 million.

What will PHVS be worth in 2030?

No reliable forecast exists that far out.

When is Pharvaris's next earnings report?

The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.

Related: Pharvaris · Financials · Dividends · Compare · AI stocks

Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.

Pharvaris (PHVS) Stock Forecast & Price Target

PHVS$33.13+0.31 +0.94%

$2.31B

Market Cap

-10.38

P/E

19.52

Forward P/E

—

Score

Price History